245 related articles for article (PubMed ID: 24835636)
1. Romosozumab: from basic to clinical aspects.
Minisola S
Expert Opin Biol Ther; 2014 Sep; 14(9):1225-8. PubMed ID: 24835636
[TBL] [Abstract][Full Text] [Related]
2. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
3. Update on romosozumab : a humanized monoclonal antibody to sclerostin.
Costa AG; Bilezikian JP; Lewiecki EM
Expert Opin Biol Ther; 2014 May; 14(5):697-707. PubMed ID: 24665957
[TBL] [Abstract][Full Text] [Related]
4. Romosozumab for the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
Soen S
Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
[TBL] [Abstract][Full Text] [Related]
6. Anti-sclerostin - is there an indication?
Larsson S
Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
[TBL] [Abstract][Full Text] [Related]
7. Profile of romosozumab and its potential in the management of osteoporosis.
Lim SY; Bolster MB
Drug Des Devel Ther; 2017; 11():1221-1231. PubMed ID: 28458516
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies for treating osteoporosis.
Faienza MF; Chiarito M; D'amato G; Colaianni G; Colucci S; Grano M; Brunetti G
Expert Opin Biol Ther; 2018 Feb; 18(2):149-157. PubMed ID: 29113523
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
Bhattacharyya S; Pal S; Chattopadhyay N
Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
[TBL] [Abstract][Full Text] [Related]
10. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
Marini F; Giusti F; Palmini G; Brandi ML
Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
12. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
Canalis E
Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin Inhibition in the Management of Osteoporosis.
Appelman-Dijkstra NM; Papapoulos SE
Calcif Tissue Int; 2016 Apr; 98(4):370-80. PubMed ID: 27016922
[TBL] [Abstract][Full Text] [Related]
15. [Anti-sclerostin antibodies].
Okazaki R
Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
Quemerais-Durieu MA; Kerlan V; Chabre O
Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
[TBL] [Abstract][Full Text] [Related]
17. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
[TBL] [Abstract][Full Text] [Related]
18. Biological agents in management of osteoporosis.
Tella SH; Gallagher JC
Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
[TBL] [Abstract][Full Text] [Related]
19. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
Front Immunol; 2018; 9():2467. PubMed ID: 30410490
[TBL] [Abstract][Full Text] [Related]
20. Future directions for new medical entities in osteoporosis.
Ferrari S
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):859-70. PubMed ID: 25432357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
